Why Is LIQUIDIA CORP (LQDA) Stock Down Today?

Liquidia Corp (LQDA) fell 57.19% to $30.26 in a single session, marking one of the stock's worst days on record. The sharp decline followed a court ruling in favor of United Therapeutics Corporation in a patent litigation case involving Liquidia's YUTREPIA product. The ruling upheld two key patent claims and concluded that Liquidia infringed on United Therapeutics’ intellectual property, triggering a significant sell-off.

What Happened

The Delaware court ruled that Liquidia violated two of United Therapeutics’ patent claims, a decision that led to an immediate and severe drop in LQDA’s share price. United Therapeutics’ stock, by contrast, rose approximately 13% on the same day. Liquidia CEO Roger Jeffs stated the company disagrees with the ruling and plans to pursue appellate options. A Form 8-K filed by Liquidia on September 30 confirmed the court’s decision and outlined related financial statements. The ruling has raised legal uncertainty for Liquidia, particularly regarding its YUTREPIA product, which has been a key driver of recent revenue growth.

What The Data Shows

Over the past 8 trading sessions, the stock had risen 7.7%, moving from $66.53 to $71.64. However, the recent drop erased roughly $3.6 billion in market value. Liquidia’s fundamentals remain strong, with a trailing twelve-month revenue increase of 2233.6% and a net margin of 30.7%. Despite this, the stock has traded between $21.35 and $93.61 over the past 52 weeks. Insiders sold a total of $56.9 million in shares over the last 90 days, with the most recent filing on September 15. Meanwhile, the 52-week tape showed 16 fresh 52-week lows on September 30, reflecting the stock’s recent volatility.

What To Watch

Liquidia’s next steps in the appellate process will be closely monitored. The company has not yet announced an earnings date, but coverage of its legal and financial developments is expected to remain active in the coming weeks.